Laidlaw Capital Markets is pleased to announce today’s pricing of a $90,000,000 Follow-On Offering for Ziopharm Oncology (ZIOP). Laidlaw proudly served as Co-Manager alongside Jefferies, who was Sole-Book Runner on the transaction.

See full Press Release on Ziopharm Website